Clinical trials: Durvalumab + Tremelimumab Combination Treatment, Pulmonary Sarcomatoid Carcinoma, NSCLC
Durvalumab + Tremelimumab Combination Treatment, Pulmonary Sarcomatoid Carcinoma, NSCLC
Pulmonary sarcomatoid_MEDI4736+Treme
To understand efficacy of Durvalumab(MEDI4736)+ Tremelimumab in Metastatic/relapsed pulmonary sarcomatoid carcinoma
- Trial name
- NCT03022500
- Testing
- durvalumab + tremelimumab
- Where
- South Korea
- Volunteers
- 32 people
- Sponsor
- Seoul National University Hospital